Dr. Toby Michael Maher, MD

Dr. Maher practices at Keck Hospital of USC in Los Angeles, California, part of University of Southern California.

Dr. Maher's NPI, 1982221958, was assigned on June 25, 2020. Dr. Maher graduated from University of Southampton Faculty of Medicine in 1998. Dr. Maher holds California license SPI-643.

Dr. Maher's primary practice is Keck Hospital of USC, at 1500 San Pablo Street, Los Angeles, CA 90033 in Los Angeles County. The practice phone is (323) 442-8656.

Dr. Maher's primary practice is Keck Hospital of USC in Los Angeles, California, part of University of Southern California. Dr. Maher is also affiliated with USC Verdugo Hills Hospital. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Maher to 2 more hospitals, 1 group practice or clinic, 1 other site and 1 urgent care center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Maher practices, 7 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Maher's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Maher is licensed in California.

Dmand AI lists asthma, bronchitis, chronic lung disease, chronic obstructive pulmonary disease (COPD), chronic respiratory failure, pneumonia, pulmonary fibrosis and pulmonary heart disease among the conditions Dr. Maher treats.

CMS data shows 753 Medicare services from Dr. Maher across 6 procedure codes in 2024, for 284 Medicare patients. Medicare paid $56,939 for them.

CMS counts 284 Medicare patients who saw Dr. Maher in 2024. The largest group is 65 to 74, with 120 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 39% are also on Medicaid. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Maher's median patient age at 70, with 58% women.

In 2024, Dr. Maher wrote 2,018 Medicare Part D claims for 255 patients. 58% of them were for generic drugs. CMS names the drug for 1,778 of them, across 30 drugs with 11 or more claims each, at $6,216,543 in total drug cost. In 2023, CMS named 1,078 claims across 21 drugs.

Dr. Maher accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Maher as offering telehealth.

Dmand AI links 140 papers to Dr. Maher, published from 2011 to 2025. 2019 was the busiest year, with 24. The most frequent topics are Idiopathic Pulmonary Fibrosis and Lung Diseases, Interstitial. Dr. Maher has published most often in Eur Respir J. Dr. Maher's most frequent co-authors are Imre Noth, MD, Ganesh Raghu, MD and David Joshua Lederer, MD.

Dmand AI links Dr. Maher to 8 clinical trials, 3 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis and Fibrosis. Royal Brompton & Harefield NHS Foundation Trust sponsors the most, 2. Open Payments lists research payments to Dr. Maher that name 3 trials.

CMS Open Payments shows 385 general payments to Dr. Maher from 20 drug and device companies from 2020 to 2025. Consulting fees make up the largest share, 85% of the total. AstraZeneca Pharmaceuticals LP paid the most, $672,168. It also lists 5 research payments totaling $13,369 from 2023 to 2025, naming 3 clinical trials.

Dr. Maher graduated from University of Southampton Faculty of Medicine in 1998.

Dr. Maher is in network with 6 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.